Virological characteristics of the SARS-CoV-2 KP.2 variant
[...]as of the beginning of April, 2024, the estimated variant frequency of KP.2 has already reached 20% in the UK (appendix p 15). Altogether, these results suggest that the increased immune escape ability of KP.2 contributes to its higher Re compared with JN.1. YKa, KU, YKo, and KO contributed equ...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2024-07, Vol.24 (7), p.e416-e416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e416 |
|---|---|
| container_issue | 7 |
| container_start_page | e416 |
| container_title | The Lancet infectious diseases |
| container_volume | 24 |
| creator | Kaku, Yu Uriu, Keiya Kosugi, Yusuke Okumura, Kaho Yamasoba, Daichi Uwamino, Yoshifumi Kuramochi, Jin Sadamasu, Kenji Yoshimura, Kazuhisa Asakura, Hiroyuki Nagashima, Mami Ito, Jumpei Sato, Kei |
| description | [...]as of the beginning of April, 2024, the estimated variant frequency of KP.2 has already reached 20% in the UK (appendix p 15). Altogether, these results suggest that the increased immune escape ability of KP.2 contributes to its higher Re compared with JN.1. YKa, KU, YKo, and KO contributed equally to this study. |
| doi_str_mv | 10.1016/S1473-3099(24)00298-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060384233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309924002986</els_id><sourcerecordid>3069816201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-45026698188caab6ae8fce398d1cb9f45e5075e12cdd7114aa8b5172d18c03453</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRrF8_QQl4qYfo7Fey8SJS_EJBsep12WwmdiXN1t1U8N-bturBi6cZhmdmXh5C9ikcU6DZyZiKnKccimLIxBEAK1SarZGtfixSIWS-vuxXyIBsx_gGQHMKYpMMuMoVA5Bb5PTFBd_4V2dNk9iJCcZ2GFzsnI2Jr5Nugsn4_HGcjvxLypLbh2OWfJjgTNvtko3aNBH3vusOeb68eBpdp3f3Vzej87vUcsa7VEhgWVYoqpQ1pswMqtoiL1RFbVnUQqKEXCJltqpySoUxqpQ0ZxVVFriQfIcMV3dnwb_PMXZ66qLFpjEt-nnUHDLgSjDOe_TwD_rm56Ht0y2oPkPGgPaUXFE2-BgD1noW3NSET01BL-TqpVy9MKeZ0Eu5Ouv3Dr6vz8spVr9bPzZ74GwFYK_jw2HQ0TpsLVYuoO105d0_L74AiqiFjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3069816201</pqid></control><display><type>article</type><title>Virological characteristics of the SARS-CoV-2 KP.2 variant</title><source>Elsevier ScienceDirect Journals</source><creator>Kaku, Yu ; Uriu, Keiya ; Kosugi, Yusuke ; Okumura, Kaho ; Yamasoba, Daichi ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Sadamasu, Kenji ; Yoshimura, Kazuhisa ; Asakura, Hiroyuki ; Nagashima, Mami ; Ito, Jumpei ; Sato, Kei</creator><creatorcontrib>Kaku, Yu ; Uriu, Keiya ; Kosugi, Yusuke ; Okumura, Kaho ; Yamasoba, Daichi ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Sadamasu, Kenji ; Yoshimura, Kazuhisa ; Asakura, Hiroyuki ; Nagashima, Mami ; Ito, Jumpei ; Sato, Kei ; The Genotype to Phenotype Japan (G2P-Japan) Consortium ; Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><description>[...]as of the beginning of April, 2024, the estimated variant frequency of KP.2 has already reached 20% in the UK (appendix p 15). Altogether, these results suggest that the increased immune escape ability of KP.2 contributes to its higher Re compared with JN.1. YKa, KU, YKo, and KO contributed equally to this study.</description><identifier>ISSN: 1473-3099</identifier><identifier>ISSN: 1474-4457</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(24)00298-6</identifier><identifier>PMID: 38782005</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Consortia ; Proteins ; R&D ; Research & development ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2024-07, Vol.24 (7), p.e416-e416</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-45026698188caab6ae8fce398d1cb9f45e5075e12cdd7114aa8b5172d18c03453</citedby><cites>FETCH-LOGICAL-c323t-45026698188caab6ae8fce398d1cb9f45e5075e12cdd7114aa8b5172d18c03453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309924002986$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38782005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Okumura, Kaho</creatorcontrib><creatorcontrib>Yamasoba, Daichi</creatorcontrib><creatorcontrib>Uwamino, Yoshifumi</creatorcontrib><creatorcontrib>Kuramochi, Jin</creatorcontrib><creatorcontrib>Sadamasu, Kenji</creatorcontrib><creatorcontrib>Yoshimura, Kazuhisa</creatorcontrib><creatorcontrib>Asakura, Hiroyuki</creatorcontrib><creatorcontrib>Nagashima, Mami</creatorcontrib><creatorcontrib>Ito, Jumpei</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>The Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><title>Virological characteristics of the SARS-CoV-2 KP.2 variant</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>[...]as of the beginning of April, 2024, the estimated variant frequency of KP.2 has already reached 20% in the UK (appendix p 15). Altogether, these results suggest that the increased immune escape ability of KP.2 contributes to its higher Re compared with JN.1. YKa, KU, YKo, and KO contributed equally to this study.</description><subject>Consortia</subject><subject>Proteins</subject><subject>R&D</subject><subject>Research & development</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkE1Lw0AQhhdRrF8_QQl4qYfo7Fey8SJS_EJBsep12WwmdiXN1t1U8N-bturBi6cZhmdmXh5C9ikcU6DZyZiKnKccimLIxBEAK1SarZGtfixSIWS-vuxXyIBsx_gGQHMKYpMMuMoVA5Bb5PTFBd_4V2dNk9iJCcZ2GFzsnI2Jr5Nugsn4_HGcjvxLypLbh2OWfJjgTNvtko3aNBH3vusOeb68eBpdp3f3Vzej87vUcsa7VEhgWVYoqpQ1pswMqtoiL1RFbVnUQqKEXCJltqpySoUxqpQ0ZxVVFriQfIcMV3dnwb_PMXZ66qLFpjEt-nnUHDLgSjDOe_TwD_rm56Ht0y2oPkPGgPaUXFE2-BgD1noW3NSET01BL-TqpVy9MKeZ0Eu5Ouv3Dr6vz8spVr9bPzZ74GwFYK_jw2HQ0TpsLVYuoO105d0_L74AiqiFjQ</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Kaku, Yu</creator><creator>Uriu, Keiya</creator><creator>Kosugi, Yusuke</creator><creator>Okumura, Kaho</creator><creator>Yamasoba, Daichi</creator><creator>Uwamino, Yoshifumi</creator><creator>Kuramochi, Jin</creator><creator>Sadamasu, Kenji</creator><creator>Yoshimura, Kazuhisa</creator><creator>Asakura, Hiroyuki</creator><creator>Nagashima, Mami</creator><creator>Ito, Jumpei</creator><creator>Sato, Kei</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Virological characteristics of the SARS-CoV-2 KP.2 variant</title><author>Kaku, Yu ; Uriu, Keiya ; Kosugi, Yusuke ; Okumura, Kaho ; Yamasoba, Daichi ; Uwamino, Yoshifumi ; Kuramochi, Jin ; Sadamasu, Kenji ; Yoshimura, Kazuhisa ; Asakura, Hiroyuki ; Nagashima, Mami ; Ito, Jumpei ; Sato, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-45026698188caab6ae8fce398d1cb9f45e5075e12cdd7114aa8b5172d18c03453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Consortia</topic><topic>Proteins</topic><topic>R&D</topic><topic>Research & development</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaku, Yu</creatorcontrib><creatorcontrib>Uriu, Keiya</creatorcontrib><creatorcontrib>Kosugi, Yusuke</creatorcontrib><creatorcontrib>Okumura, Kaho</creatorcontrib><creatorcontrib>Yamasoba, Daichi</creatorcontrib><creatorcontrib>Uwamino, Yoshifumi</creatorcontrib><creatorcontrib>Kuramochi, Jin</creatorcontrib><creatorcontrib>Sadamasu, Kenji</creatorcontrib><creatorcontrib>Yoshimura, Kazuhisa</creatorcontrib><creatorcontrib>Asakura, Hiroyuki</creatorcontrib><creatorcontrib>Nagashima, Mami</creatorcontrib><creatorcontrib>Ito, Jumpei</creatorcontrib><creatorcontrib>Sato, Kei</creatorcontrib><creatorcontrib>The Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><creatorcontrib>Genotype to Phenotype Japan (G2P-Japan) Consortium</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaku, Yu</au><au>Uriu, Keiya</au><au>Kosugi, Yusuke</au><au>Okumura, Kaho</au><au>Yamasoba, Daichi</au><au>Uwamino, Yoshifumi</au><au>Kuramochi, Jin</au><au>Sadamasu, Kenji</au><au>Yoshimura, Kazuhisa</au><au>Asakura, Hiroyuki</au><au>Nagashima, Mami</au><au>Ito, Jumpei</au><au>Sato, Kei</au><aucorp>The Genotype to Phenotype Japan (G2P-Japan) Consortium</aucorp><aucorp>Genotype to Phenotype Japan (G2P-Japan) Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virological characteristics of the SARS-CoV-2 KP.2 variant</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>24</volume><issue>7</issue><spage>e416</spage><epage>e416</epage><pages>e416-e416</pages><issn>1473-3099</issn><issn>1474-4457</issn><eissn>1474-4457</eissn><abstract>[...]as of the beginning of April, 2024, the estimated variant frequency of KP.2 has already reached 20% in the UK (appendix p 15). Altogether, these results suggest that the increased immune escape ability of KP.2 contributes to its higher Re compared with JN.1. YKa, KU, YKo, and KO contributed equally to this study.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>38782005</pmid><doi>10.1016/S1473-3099(24)00298-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2024-07, Vol.24 (7), p.e416-e416 |
| issn | 1473-3099 1474-4457 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3060384233 |
| source | Elsevier ScienceDirect Journals |
| subjects | Consortia Proteins R&D Research & development Severe acute respiratory syndrome coronavirus 2 Vaccines |
| title | Virological characteristics of the SARS-CoV-2 KP.2 variant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A20%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virological%20characteristics%20of%20the%20SARS-CoV-2%20KP.2%20variant&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Kaku,%20Yu&rft.aucorp=The%20Genotype%20to%20Phenotype%20Japan%20(G2P-Japan)%20Consortium&rft.date=2024-07-01&rft.volume=24&rft.issue=7&rft.spage=e416&rft.epage=e416&rft.pages=e416-e416&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(24)00298-6&rft_dat=%3Cproquest_cross%3E3069816201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3069816201&rft_id=info:pmid/38782005&rft_els_id=S1473309924002986&rfr_iscdi=true |